CD276 and neoplasm: As an immune-regulating member of the B7 family, a tumor cell surface molecule, and a tumor vessel endothelial marker [23,24,25], CD276 has emerged as a potential target for NSCLC therapy, either alone or in combination with PD-1 [26,27,28].